CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating Activities
Net loss	$ (148,113)	$ (53,592)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,539	555
Stock-based compensation	77,925	10,945
Accretion of unamortized debt discount and amortization of debt issuance costs	824	9
Amortization of premium (accretion of discount) for marketable securities	984	0
Deferred income taxes	(318)	0
Change in fair value of common stock warrant liabilities	(4,462)	2,108
Changes in operating assets and liabilities:
Accounts receivable, net	267	0
Prepaid expenses and other assets	(5,676)	(4,499)
Operating lease right-of-use assets	534	(13,453)
Accounts payable	(5,613)	(4,060)
Operating lease liabilities	(473)	14,386
Other accruals and liabilities	(4,868)	8,448
Net cash used in operating activities	(83,450)	(39,153)
Investing Activities
Purchases of property and equipment, including internal-use software	(107)	(659)
Purchases of marketable securities	(149,495)	0
Proceeds from maturities of marketable securities	83,265	0
Proceeds from sales of marketable securities	25,593	0
Net cash used in investing activities	(40,744)	(659)
Financing Activities
Principal payments on finance leases obligations	(840)	0
Payments for debt issuance costs	(1,976)	0
Proceeds from issuance of common stock in follow-on offering, net of underwriting commissions, and offering costs	0	402,817
Payments made towards deferred offering costs	0	(13,167)
Net proceeds from exercise of stock options and issuance of common stock	236	12
Net cash (used in) provided by financing activities	(2,580)	389,662
Net change in cash, cash equivalents and restricted cash	(126,774)	349,850
Cash, cash equivalents and restricted cash – beginning of year	244,252	265,648
Cash, cash equivalents and restricted cash – end of period	117,478	615,498
Cash paid during the period for:
Interest	86	15
Noncash investing and financing activities:
Deferred offering costs and issuance costs in accounts payable and accrued liabilities	28	1,449
Warrant exercise receivable	0	104,558
Warrant liability reclassified to additional paid-in capital	$ 0	$ 67,961